Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma

Medical and Pediatric Oncology

Volumn 36, Issue 1, 2001, Pages 213-219

  Hero, B ^a   Hunneman, D H ^a   Gahr, M ^b   Berthold, F ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Bone marrow; Minimal residual disease; Neuroblastoma; PBSC; RT PCR; Tyrosine hydroxylase

Indexed keywords

TYROSINE 3 MONOOXYGENASE;

ADVANCED CANCER; ANIMAL CELL; BONE MARROW CELL; CELL ISOLATION; CLONOGENIC ASSAY; CONFERENCE PAPER; CONTAMINATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MESSENGER RNA SYNTHESIS; MINIMAL RESIDUAL DISEASE; NEUROBLASTOMA; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE SPECIFICITY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LIFE TABLES; NEOPLASM CIRCULATING CELLS; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; NEUROBLASTOMA; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TYROSINE 3-MONOOXYGENASE;

EID: 0035173552     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-911X(20010101)36:1<213::AID-MPO1052>3.0.CO;2-9     Document Type: Conference Paper

References (35)

1. Prognostic value of immunocytologic detection of bone marrow metastasis in neuroblastoma
2. Myeloablative chemoradiotherapy versus continued chemotherapy for high risk neuroblastoma
3. 1070 Myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions
4. Clonogenicity of circulating neuroblastoma cells: Implications regarding peripheral blood stem cell transplantation
5. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients
6. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells
7. Autologous transplantation with peripheral blood stem cells: A review of clinical results
8. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma
9. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells
10. High-dose chemotherapy with hematopoietic stem cell rescue for non-Hodgkin's lymphoma: Evaluation of event-free survival bases on histologic subtype and rescue product
11. Detection of tyrosine hydroxylase mRNA and minimal neuroblastoma cells by the reverse transcription-polymerase chain reaction
12. Neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA
13. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA
14. The molecular detection of tumour cells
15. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma
16. Improved methods using the reverse transcriptase polymerase chain reaction to detect tumor cells
17. Histopathologic prognostic factors in neuroblastic tumours; definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas
18. Prognostic significance of histopathologic features of neuroblastoma: A grading system based on the review of 211 cases from the Pediatric Oncology Group
19. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors
20. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma
21. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors
22. Detection of tumour cells in peripheral blood stem cell harvests after G-CSF in children undergoing standard chemotherapy for high risk neuroblastoma and Ewing's sarcoma
23. Dose intensive use of cyclophosphamide in ablation of neuroblastoma
24. Myeloablative chemoradiotherapy and autologous bone marrow infusion for treatment of neuroblastoma: Factors influencing engraftment
25. Stem cell mobilization, collection and transplantation in patients with pediatric tumors
26. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment
27. The detection of disseminated tumor cells in bone marrow from colorectal-cancer patients by a cytokeratin-20-specific nested reverse-transcriptase-polymerase-chain reaction is related to the stage of disease
28. Polymerase chain reaction detection of melanoma cells in the circulation: Relation to clinical stage, surgical treatment, and recurrence from melanoma
29. Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing's tumor. Societe Francaise d'Oncologie Pediatrique
30. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
31. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
32. Detection of N-myc gene amplification by fluorescence in situ hybridization: Diagnostic utility for neuroblastoma
33. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas
34. Allelic loss of chromosome 1p as a predictor of unfavourable outcome in patients with neuroblastoma
35. Promiscuous translocations of chromosome arm 17q in human neuroblastomas